Ena Novakovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ena Novakovic has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Josiah Bennett
School of Medicine, Mercer University School of Medicine, Savannah, GA 31404, USA
2 shared publications - Julian Gendreau
Department of Neurological Surgery, Oregon Health & Science University, Portland, USA
2 shared publications - Mickey E. Abraham
Department of Neurosurgery, UC San Diego School of Medicine, La Jolla, United States
2 shared publications - Antonios Mammis
NYU Grossman School of Medicine
1 shared publication - Dana Poloni
Department of Surgery, Eisenhower Army Medical Center, Augusta, GA 30905, USA
1 shared publication - Huey Huynh
Neurological Surgery, Mercer University School of Medicine, Macon, USA
1 shared publication
Latest Publications
- Open Access
- 27 June 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (7) , 1050
The Current State of Radiotherapy for Pediatric Brain Tumors: An Overview of Post-Radiotherapy Neurocognitive Decline and Outcomes
Tumors of the central nervous system are the most common solid malignancies diagnosed in children. While common, they are also found to have some of the lowest survival rates of all malignancies. Treatment of childhood brain tumors often consists of operative gross total resection with adjuvant chemotherapy or radiotherapy. The current body of literature is largely inconclusive regarding the overall benefit of adjuvant chemo- or radiotherapy. However, it is known that both are associated with conditions that lower the quality of life in children who undergo those treatments. Chemotherapy is often associated with nausea, emesis, significant fatigue, immunosuppression, and alopecia. While radiotherapy can be effective for achieving local control, it is associated with late effects such as endocrine dysfunction, secondary malignancy, and neurocognitive decline. Advancements in radiotherapy grant both an increase in lifetime survival and an increased lifetime for survivors to contend with these late effects. In this review, the authors examined all the published literature, analyzing the results of clinical trials, case series, and technical notes on patients undergoing radiotherapy for the treatment of tumors of the central nervous system with a focus on neurocognitive decline and survival outcomes.
- 27 June 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (7) , 1050
Open AccessThe Current State of Radiotherapy for Pediatric Brain Tumors: An Overview of Post-Radiotherapy Neurocognitive Decline and Outcomes
Tumors of the central nervous system are the most common solid malignancies diagnosed in children. While common, they are also found to have some of the lowest survival rates of all malignancies. Treatment of childhood brain tumors often consists of operative gross total resection with adjuvant chemotherapy or radiotherapy. The current body of literature is largely inconclusive regarding the overall benefit of adjuvant chemo- or radiotherapy. However, it is known that both are associated with conditions that lower the quality of life in children who undergo those treatments. Chemotherapy is often associated with nausea, emesis, significant fatigue, immunosuppression, and alopecia. While radiotherapy can be effective for achieving local control, it is associated with late effects such as endocrine dysfunction, secondary malignancy, and neurocognitive decline. Advancements in radiotherapy grant both an increase in lifetime survival and an increased lifetime for survivors to contend with these late effects. In this review, the authors examined all the published literature, analyzing the results of clinical trials, case series, and technical notes on patients undergoing radiotherapy for the treatment of tumors of the central nervous system with a focus on neurocognitive decline and survival outcomes.
- Open Access
- 17 August 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , c46
Characterizing Complications of Deep Brain Stimulation Devices for the Treatment of Parkinsonian Symptoms Without Tremor: A Federal MAUDE Database Analysis
Unfortunately, after publication of this article, the authors noticed that Brian Walker's name was associated with Boston Scientific in the It was determined his name was written in a way that suggested he was involved in the production of these devices. However, he is only a sales representative for the organization. Therefore, it was removed from the article post-publication. The authors apologize for this oversight.
- 17 August 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , c46
Open AccessCharacterizing Complications of Deep Brain Stimulation Devices for the Treatment of Parkinsonian Symptoms Without Tremor: A Federal MAUDE Database Analysis
Unfortunately, after publication of this article, the authors noticed that Brian Walker's name was associated with Boston Scientific in the It was determined his name was written in a way that suggested he was involved in the production of these devices. However, he is only a sales representative for the organization. Therefore, it was removed from the article post-publication. The authors apologize for this oversight.